天津医药

天津医药 ›› 2016, Vol. 44 ›› Issue (3): 302-305.doi: 10.11958/59140

• 细胞与分子生物学 • 上一篇    下一篇

白头翁皂苷D联合索拉非尼对人肝癌细胞侵袭与转移的影响

贺武斌,苏荣健   

  1. 1 辽宁锦州， 辽宁医学院（邮编 121001）；2辽宁医学院科学实验中心
  • 收稿日期:2015-06-25 修回日期:2015-10-28 出版日期:2016-03-15 发布日期:2016-03-15
  • 通讯作者: 苏荣健 E-mail:rongjiansu@yahoo.com.cn
  • 作者简介:贺武斌（1982）， 男， 硕士在读， 主要从事肝癌的侵袭和转移研究
  • 基金资助:
    辽宁省教育厅重点实验室基金资助项目

Pulsatill Pulsatilla saponin D combined with sorafenib against hepatocellular carcinoma cell invasion and metastasis of

HE Wubin, SU Rongjian   

  1. 1 Liaoning Medical University, Jinzhou 121001, China; 2 Liaoning Medical Science Experiment Center
  • Received:2015-06-25 Revised:2015-10-28 Published:2016-03-15 Online:2016-03-15
  • Contact: SU Rongjian E-mail:rongjiansu@yahoo.com.cn

PDF (PC)

3788

摘要： [摘要]目的 探讨白头翁皂苷D联合索拉非尼对人肝癌细胞株侵袭与转移的影响。 方法 将人肝癌细胞BEL-7402分为白头翁皂苷D单药处理组、索拉非尼单药处理组及两药联合处理组，观察比较三种处理方式对肝癌细胞侵袭和转移的影响。结果 检测分析各组黏附抑制率，作用3h，索拉非尼组显著高于白头翁皂苷D组（P＜0.05或＜0.01），联合用药组显著高于索拉非尼组和白头翁皂苷D组（P＜0.01）；作用5h，白头翁皂苷D组黏附抑制率显著高于索拉非尼组（P＜0.01），并且高于白头翁皂苷D组作用3h（P＜0.01），说明两药联合对肝癌细胞的黏附抑制率具有协同作用（Q=2.33＞1.15）；检测分析各组迁移抑制率，索拉非尼单药组和两药联合组对肝癌细胞的迁移抑制率均显著高于白头翁皂苷D单药组（P＜0.01），并且两药联合组的抑制率显著高于索拉非尼单药组（P＜0.01），说明两药联合对肝癌细胞的迁移抑制作用具有协同作用（Q=1.39＞1.15）；检测分析侵袭抑制率，索拉非尼单药组和两药联合组均显著高于白头翁皂苷D组（P＜0.01），说明两药联合对肝癌细胞的侵袭抑制作用具有拮抗作用（Q=0.68＜0.85）。各组的VEGF-C、MMP-9表达情况：白头翁皂苷D单药组的MMP-9表达水平显著下降，索拉非尼组和两药联合组的VEGF-C、MMP-9及表达水平均显著下降（P＜0.05）；与白头翁皂苷D单药组比较，两药联合组的VEGF-C表达水平显著下降；两药联合组较白头翁皂苷D单药组VEGF-C水平显著下降（P＜0.05）。结论 白头翁皂苷D、索拉非尼单药以及两药联合对肝癌细胞BEL-7402细胞株的黏附、迁移、侵袭具有一定的抑制作用，且二者对肝癌细胞的黏附、迁移的抑制具有协同作用。

关键词: 肝肿瘤, 肿瘤转移, 体外研究, 药物疗法, 联合, 白头翁皂苷 D, 索拉非尼, BEL-7402

Abstract: [Abstract] Objective To investigate Pulsatilla saponin D joint sorafenib on human hepatoma cell line invasion and metastasis of influence. Methods Human hepatocellular carcinoma cell BEL-7402 into Pulsatilla saponin D single-drug treatment group to compare three treatments sorafenib monotherapy treatment group and the two-drug combination treatment group, observation methods on liver cancer cell invasion and metastasis.Results detect the adhesion inhibition rate in each group, the role of 3h, sorafenib group was significantly higher than Pulsatilla saponin D group (P <0.05 or <0.01), the combined treatment group was significantly higher than the sorafenib group and Pulsatilla saponin D group ( P <0.01); the role of 5h, Pulsatilla saponin D group was significantly higher than the adhesion inhibition sorafenib group (P <0.01), and higher than Pulsatilla saponin D group action 3h (P <0.01), described the two drugs on liver cancer cell adhesion synergistic inhibition rate (Q = 2.33> 1.15); detecting migration inhibitory rate in each group, sorafenib monotherapy group and the two-drug combination group of hepatoma cell migration inhibition were significantly higher than Pulsatilla saponin D monotherapy group (P <0.01), and the inhibition rate of two-drug combination group was significantly higher than that of sorafenib monotherapy group (P <0.01), described the two-drug combination migration of hepatoma cell line has a synergistic effect (Q = 1.39> 1.15); Detection of invasion inhibition rate, sorafenib monotherapy group and the two-drug combination group were significantly higher than Pulsatilla saponin D group (P <0.01), described the two drugs on liver cancer cell invasion inhibition of antagonistic effect (Q = 0.68 <0.85). Each group of VEGF-C, MMP-9 expression: MMP-9 expression levels Pulsatilla saponin D monotherapy significantly decreased sorafenib group and two-drug combination group VEGF-C, MMP-9 expression was significantly decreased (P <0.05); compared with Pulsatilla saponin D monotherapy group, VEGF-C expression levels of the two-drug combination group was significantly decreased; two-drug combination group Baitouweng saponin D monotherapy VEGF-C level decreased significantly (P <0.05). Conclusion Pulsatilla saponin D, sorafenib monotherapy as well as combination of two drugs on liver cancer cells BEL-7402 cell line adhesion, migration, invasion has a certain extent, and both hepatoma cell adhesion, migration inhibitory synergistic .

Key words: Pulsatilla saponin D, sorafenib, hepatoma cells, Invasion, Metastasis